SPROライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:49):

Stats
本日の出来高	116 817
平均出来高	323 929
時価総額	78.15M
EPS	$0 ( 2024-03-13 )
次の収益日	( $-0.0700 ) 2024-05-09
Last Dividend	$0.0150 ( 2015-09-16 )
Next Dividend	$0 ( N/A )
P/E	3.37
ATR14	$0.00800 (0.55%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Keutzer Timothy	Buy	239 731	Common Stock
2024-02-02	Keutzer Timothy	Sell	30 971	Common Stock
2024-02-02	Mahadevia Ankit	Sell	63 795	Common Stock
2024-02-01	Joseph Tamara L	Buy	239 731	Common Stock
2024-02-02	Joseph Tamara L	Sell	30 906	Common Stock

INSIDER POWER
59.24
Last 96 transactions
Buy: 6 234 250 \| Sell: 2 240 393

ボリューム相関

長: -0.24 (neutral)

短: -0.48 (neutral)

Signal:(49.047) Neutral

Spero Therapeutics Inc 相関

10 最も正の相関
AKYA	0.855
COLB	0.855
CARE	0.85
ARQT	0.842
CBAN	0.835
FSEA	0.833
FBMS	0.832
FRBA	0.826
FBIZ	0.825
BIRD	0.823

10 最も負の相関
BNIXU	-0.902
OFLX	-0.802

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Spero Therapeutics Inc 相関 - 通貨/商品

-0.30
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.19
( neutral )

-0.66
( moderate negative )

0.34
( neutral )

Spero Therapeutics Inc 財務諸表

Annual	2023
収益:	$96.74M
総利益:	$96.37M (99.62 %)
EPS:	$0.430

FY	2023
収益:	$96.74M
総利益:	$96.37M (99.62 %)
EPS:	$0.430

FY	2022
収益:	$48.58M
総利益:	$47.03M (96.82 %)
EPS:	$-1.280

FY	2021
収益:	$18.26M
総利益:	$0.00 (0.00 %)
EPS:	$-2.91

Financial Reports:

No articles found.

Spero Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Spero Therapeutics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.56 - good (75.57%) | Divividend Growth Potential Score: 0.385 - No dividend growth expected in the near future

Information

First Dividend	$0.0100	2010-03-30
Last Dividend	$0.0150	2015-09-16
Next Dividend	$0	N/A
Payout Date	2015-10-07
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$0.285	--
Avg. Dividend % Per Year	0.00%	--
Score	2.92	--
Div. Sustainability Score	7.56
Div.Growth Potential Score	0.385
Div. Directional Score	3.97	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.92

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.240	1.500	5.19	7.79	[0 - 0.5]
returnOnAssetsTTM	0.130	1.200	5.66	6.79	[0 - 0.3]
returnOnEquityTTM	0.339	1.500	7.34	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.42	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.05	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0304	-1.500	9.49	-10.00	[0 - 0.6]
interestCoverageTTM	-20.59	1.000	-8.74	-8.74	[3 - 30]
operatingCashFlowPerShareTTM	-0.623	2.00	-0.208	-0.415	[0 - 30]
freeCashFlowPerShareTTM	-0.623	2.00	-0.311	-0.623	[0 - 20]
debtEquityRatioTTM	0.0519	-1.500	9.79	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.811	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.200	1.000	8.00	8.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-5.95	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.542	0.800	9.72	7.78	[0.5 - 2]
Total Score				7.56

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.26	1.000	9.77	0	[1 - 100]
returnOnEquityTTM	0.339	2.50	8.29	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.623	2.00	-0.208	-0.623	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.623	2.00	-0.208	-0.415	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.00900	1.500	-3.39	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.334	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.385

Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.